Tevogen Bio Holdings Inc. (TVGN) Cash Flow Statement
Where TVGN’s cash came from and went, FY2026
June 30, 2026 · U.S. dollars- Cash from operations
- −$12.3M
- Capital expenditures
- $64,439
- Free cash flow
- −$12.4M
- Returned to shareholders
- —
- Change in cash
- −$730,623 cash at year-end $552,372
Drawn to scale: where the cash came from and how it was used. Hover for values.
TVGN operating cash flow, capex and free cash flow
TVGN cash flow trends, FY2022–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$5.3MFY2022 | −$12.3MFY2026 | — | |
| Capital expenditures | $109,727FY2022 | $64,439FY2026 | −12.5%/yr | |
| Free cash flow | −$5.4MFY2022 | −$12.4MFY2026 | — | |
| Stock-based compensation | $582,408FY2022 | $16.2MFY2026 | +129.7%/yr | |
| Share buybacks (net) | $0FY2023 | $343.0MFY2024 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
TVGN cash flow by activity
TVGN net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
TVGN cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Operating activities | |||||
| Net income | −$26.3M | −$13.7M | −$60.5M | −$22.0M | −$15.6M |
| Depreciation & amortization | $509,197 | $403,581 | $378,357 | $230,823 | $9,377 |
| Stock-based compensation | $16.2M | $40.8M | $0 | $4.6M | $582,408 |
| Change in working capital | −$2.7M | −$5,487 | $293,205 | −$96,922 | −$1.2M |
| Other non-cash items | −$60,701 | −$39.4M | $51.6M | $8.7M | $11.0M |
| Cash from operating activities | −$12.3M | −$12.0M | −$8.2M | −$8.7M | −$5.3M |
| Investing activities | |||||
| Capital expenditures | −$64,439 | $0 | −$133,000 | −$479,042 | −$109,727 |
| Investments (net) | — | $0 | $342.9M | −$479,042 | −$109,727 |
| Acquisitions & other investing | $0 | — | −$342.9M | $479,042 | $109,727 |
| Cash from investing activities | −$64,439 | — | −$133,000 | −$479,042 | −$109,727 |
| Financing activities | |||||
| Share repurchases & issuance (net) | — | — | −$343.0M | $0 | — |
| Net borrowing (repayment) | $3.4M | $1.0M | $4.0M | $0 | $12.5M |
| Shares issued | $4.9M | $11.0M | $0 | $0 | $0 |
| Other financing | $3.4M | $229,328 | $342.9M | $7.5M | $0 |
| Cash from financing activities | $11.7M | $12.2M | $3.9M | $7.5M | $12.5M |
| Summary | |||||
| Net change in cash | −$730,623 | $230,598 | −$4.4M | −$1.6M | $7.1M |
| Cash at end of period | $552,372 | $1.3M | $1.1M | $5.5M | $7.1M |
| Free cash flow | −$12.4M | −$12.0M | −$8.3M | −$9.1M | −$5.4M |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$5.8M | −$5.4M | −$4.7M | −$5.7M | −$5.5M | −$10.4M | −$9.4M | −$5.9M | −$9.7M | $11.3M | −$3.6M | −$3.9M |
| Depreciation & amortization | $60,144 | $59,051 | $85,786 | $291,417 | $26,592 | $105,402 | $103,547 | $218,930 | −$17,199 | $98,303 | $100,869 | $93,579 |
| Stock-based compensation | $3.3M | $2.8M | $2.4M | $3.2M | $3.2M | $7.3M | $7.0M | $3.3M | $4.1M | $26.3M | — | $0 |
| Change in working capital | −$593,408 | −$170,326 | −$32,088 | −$1.1M | −$1.2M | −$349,825 | −$749,045 | −$1.1M | $1.4M | $517,838 | −$68,109 | $431,380 |
| Other non-cash items | $1,177 | −$25,831 | −$3,295 | −$329,151 | $261,025 | $10,720 | $81,348 | −$318,486 | $1.2M | −$40.4M | $1.6M | $1.6M |
| Cash from operating activities | −$3.0M | −$2.7M | −$2.2M | −$3.6M | −$3.2M | −$3.3M | −$3.0M | −$3.8M | −$3.0M | −$2.2M | −$2.0M | −$1.8M |
| Investing activities | ||||||||||||
| Capital expenditures | −$3 | −$1 | −$64,433 | −$4 | −$3 | −$3 | $0 | −$1 | $0 | −$5 | −$2 | −$2 |
| Investments (net) | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $343.0M | $0 |
| Acquisitions & other investing | — | — | −$6 | — | — | — | — | — | — | — | −$333.4M | — |
| Cash from investing activities | — | — | −$64,439 | — | — | — | — | — | — | — | $9.6M | — |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | −$333.6M | — | $333.6M | — | — | −$9.7M | −$333.3M |
| Net borrowing (repayment) | $0 | $2.0M | $0 | $0 | $1.4M | $2.0M | $0 | $1.0M | — | — | — | — |
| Shares issued | $428,253 | $873,702 | $1.8M | $3.1M | $0 | $2.0M | $2.0M | $4.0M | $2.8M | $2.2M | $0 | $0 |
| Other financing | $3.0M | $0 | $0 | $900,000 | $500,000 | $333.6M | $0 | −$333.6M | $0 | $229,328 | $10.1M | $334.2M |
| Cash from financing activities | $3.4M | $2.9M | $1.8M | $4.0M | $1.9M | $4.0M | $2.0M | $5.0M | $2.8M | $2.4M | $422,250 | $950,000 |
| Summary | ||||||||||||
| Net change in cash | $389,850 | $139,933 | −$484,722 | $351,865 | −$1.3M | $691,937 | −$1.0M | $1.2M | −$182,510 | $265,503 | $704,851 | −$208,464 |
| Cash at end of period | $1.1M | $692,305 | $552,372 | $1.0M | $685,229 | $2.0M | $1.3M | $2.3M | $1.1M | $1.3M | $1.1M | $347,546 |
| Free cash flow | −$3.0M | −$2.7M | −$2.2M | −$3.6M | −$3.2M | −$3.3M | −$3.0M | −$3.8M | −$3.0M | −$2.2M | −$2.0M | −$1.8M |
| Free cash flow margin | — | — | — | — | — | −834.1% | — | — | — | — | — | — |
| Capex / revenue | — | — | — | — | — | 0.0% | — | — | — | — | — | — |
| Operating cash flow / net income | — | — | — | — | — | — | — | — | — | −0.19 | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
TVGN cash generation
In fiscal 2026 (ended June 30, 2026), Tevogen Bio generated -$12.3 million of cash from operations and spent $0.1 million on capital expenditures, leaving free cash flow of -$12.4 million. Cash and equivalents fell by $0.7 million over the year.
Related: TVGN income statement, TVGN balance sheet. See the TVGN stock overview for the latest quote and news.
TVGN cash flow FAQ
What is Tevogen Bio's free cash flow?
Tevogen Bio's free cash flow was -$12.4 million in fiscal 2026: -$12.3 million of operating cash flow minus $0.1 million of capital expenditures It was -$12.0 million a year earlier..
How much cash does Tevogen Bio generate from operations?
Tevogen Bio generated -$12.3 million of cash from operating activities in fiscal 2026.
How much does Tevogen Bio spend on capital expenditures?
Tevogen Bio spent $0.1 million on capital expenditures in fiscal 2026.